MetaVia Reports Additional Top-Line Results From The MAD Part 2 Of Its Phase 1 Study Of DA-1726, A Novel 3:1 Ratio GLP-1 And Glucagon Dual Receptor Agonist To Treat Obesity; No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate Or QTcF Measurements Of Subjects Receiving Up To 32mg Of DA-1726 At 4-Weeks; Additional Cohorts Being Added to Determine Maximum Tolerated Dose

byBenzinga News DeskBenzinga Staff Writer

April 22, 2025 6:05 PM

18 seconds read

Take Stock Of The Week Ahead

Get all the latest Share Market trends and news to set you up for the week ahead.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!